Home > Insider Trading > Filing (0001209191-14-008252)

Filing Details

Accession Number:: 0001209191-14-008252
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-02-07 12:02:03
Reporting Period:: 2014-02-05

Filing Date:: 2014-02-07
Accepted Time:: 2014-02-07 12:02:03
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1429560	Trevena Inc	TRVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1013469	W John Littlechild	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1013473	H James Cavanaugh	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1013603	R Harold Werner	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1262326	Christopher Mirabelli	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	Yes	No	Yes	No
1262327	Augustine Lawlor	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1358990	Healthcare Ventures Viii, L.p.	C/O Healthcare Ventures Llc, 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1358991	Healthcare Partners Viii, L.p.	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No
1358992	Healthcare Partners Viii, Llc	C/O Healthcare Ventures Llc 47 Thorndike Street, Suite B1-1 Cambridge MA 02141	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-02-05	967,741	$0.00	967,741	No	4	C	Indirect	By Partnership
Common Stock	Acquisiton	2014-02-05	677,419	$0.00	1,645,160	No	4	C	Indirect	By Partnership
Common Stock	Acquisiton	2014-02-05	504,033	$0.00	2,149,193	No	4	C	Indirect	By Partnership
Common Stock	Acquisiton	2014-02-05	297,058	$7.00	2,446,251	No	4	P	Indirect	By Partnership

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Partnership
No	4	C	Indirect	By Partnership
No	4	C	Indirect	By Partnership
No	4	P	Indirect	By Partnership

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-02-05	6,000,000	$0.00	967,741	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-02-05	4,200,000	$0.00	677,419	$0.00
Common Stock	Series C Preferred Stock	Disposition	2014-02-05	3,125,000	$0.00	504,033	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of convertible preferred stock was convertible at any time, at the holder's election, into the issuer's common stock on a 6.2 to 1 basis. Effective immediately prior to the closing of the issuer's initial public offering of its common stock, each share of convertible preferred stock automatically converted on a 6.2 to 1 basis into shares of common stock of the issuer. The convertible preferred stock had no expiration date.
The securities are held of record by HealthCare Ventures VIII, L.P. ("HCVVIII"). HealthCare Partners VIII, L.P. ("HCPVIII") is the General Partner of HCVVIII and HealthCare Partners VIII, LLC (the "LLC") is the General Partner of HCPVIII. Each of James Cavanaugh, Harold Werner, John Littlechild, Christopher Mirabelli and Augustine Lawlor are the managing directors of the LLC and exercise shared voting and investment power with respect to the shares owned by HCVVIII. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. Dr. Mirabelli is also a director of the issuer.
Includes one share of common stock issued to the reporting persons in connection with the aggregation of fractional shares.
These shares were purchased by HCVVIII.
Please note that each of the reporting persons are no longer subject to Section 16 reporting requirements with the exception of Christopher Mirabelli, who will have an ongoing reporting obligation as a director of the issuer.